Seres Therapeutics (NASDAQ:MCRB) Posts Quarterly Earnings Results, Misses Estimates By $0.63 EPS

Seres Therapeutics (NASDAQ:MCRB) announced its earnings results on Wednesday. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.63), FiscalAI reports. The firm had revenue of $0.59 million during the quarter, compared to the consensus estimate of $6.35 million. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%.

Seres Therapeutics Stock Performance

MCRB stock remained flat at $2.09 during trading on Thursday. 94,587 shares of the company traded hands, compared to its average volume of 71,164. The stock has a market capitalization of $20.99 million, a PE ratio of -0.86 and a beta of 0.44. Seres Therapeutics has a one year low of $1.67 and a one year high of $29.98. The stock has a 50-day simple moving average of $3.45 and a 200 day simple moving average of $6.98.

Wall Street Analysts Forecast Growth

MCRB has been the topic of several recent research reports. Wall Street Zen raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.